• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Jill Colquitt, Jeremy O. Jones, S C Tan, A. L. Takeda, Andrew J Clegg, Alison L. Price
  • Medicine
  • Health technology assessment
  • 2008 (First Publication: 1 May 2008)
  • OBJECTIVES To assess the clinical effectiveness and cost-effectiveness of ranibizumab and pegaptanib for subfoveal choroidal neovascularisation (CNV) associated with wet age-related macularContinue Reading
  • Joanna Picot, Debbie Hartwell, Pamela Harris, Diana Mendes, Andrew J Clegg, A. L. Takeda
  • Medicine
  • Health technology assessment
  • 2012 (First Publication: 1 April 2012)
  • BACKGROUND Severe acute malnutrition (SAM) arises as a consequence of a sudden period of food shortage and is associated with loss of a person's body fat and wasting of their skeletal muscle. Many ofContinue Reading
  • A. L. Takeda, Emma Loveman, +4 authors Crystal Green
  • Medicine
  • International journal of geriatric psychiatry
  • 2006
  • BACKGROUND The use of cholinesterase inhibitors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clinical Evidence (NICE). This article provides the latestContinue Reading
  • A. L. Takeda, Jeremy O. Jones, Emma Loveman, S C Tan, Andrew J Clegg
  • Medicine
  • Health technology assessment
  • 2007 (First Publication: 1 May 2007)
  • OBJECTIVES To assess the clinical effectiveness and cost-effectiveness of gemcitabine, used in combination with paclitaxel, as a second-line treatment for people with metastatic breast cancer whoContinue Reading
  • A. L. Takeda, Jeremy O. Jones, Jonathan S. Shepherd, Peter Davidson, Alison L. Price
  • Medicine
  • Journal of viral hepatitis
  • 2007 (First Publication: 1 February 2007)
  • Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively. The aimContinue Reading